孟鲁司特对毛细支气管炎患儿白三烯水平的影响

目的 观察孟鲁司特对毛细支气管炎患儿治疗前后血清白三烯B4 及尿白三烯E4 水平的影响。方法 将2014 年6~12 月诊断为毛细支气管炎的患儿75 例随机分为孟鲁司特治疗组(n=38)和对照组(n=37),两组患儿均进行常规综合治疗,治疗组在此基础上加用孟鲁司特片(4 mg),每晚1 次,连续口服7 d;采用ELISA 法检测两组治疗前后血清白三烯B4 及尿白三烯E4 水平,并进行临床疗效分析;采用Pearson 分析对血清白三烯B4 及尿白三烯E4 水平进行相关性分析。结果 治疗后两组患儿血清白三烯B4 及尿白三烯E4 水平比治疗前明显下降(PPPr=0.723,P结论 孟鲁司特治疗毛细支气管炎临床疗效确切,其作用机制与降低毛细支气管炎患儿血清白三烯B4 及尿白三烯E4 水平有关。

Clinical efficacy of montelukast for the treatment of bronchiolitis in infants

Objective To observe the effect of montelukast treatment on levels of serum leukotriene B4 and urinary leukotriene E4 in infants with bronchiolitis. Methods Seventy-five children who were diagnosed with bronchiolitis between June 2014 and December 2014 were randomly assigned into two groups, one with thirty-eight cases as the montelukast treatment group and another thirty-seven cases as the control group. All of the children were given routine medical treatment. The children in the montelukast treatment group were additionally given montelukast daily (4 mg once a day, for 7 days). The serum leukotriene B4 and urinary leukotriene E4 levels were measured using ELISA before and after treatment. The relationship between serum leukotriene B4 and urinary leukotriene E4 levels was analyzed by Peason correlation analysis. Results After 7 days of treatment, the serum leukotriene B4 and urinary leukotriene E4 levels in the montelukast treatment and control groups were significantly reduced compared with before treatment (P<0.05). The montelukast treatment group showed significantly lower serum leukotriene B4 and urinary leukotriene E4 levels than the control group (P<0.05). The remission time of cough, wheezing and lung wheezes and the length of hospital stay in the montelukast treatment group were significantly shortened compared with the control group (P<0.05). There was a positive correlation between serum leukotriene B4 and urinary leukotriene E4 levels (r=0.723, P<0.05). Conclusions Montelukast has a reliable clinical curative efficacy for bronchiolitis in infants, possibly by decreasing serum leukotriene D4 and urinary leukotriene E4 levels.